“ϊ–{–ςŠw‰ο ‘ζ136”N‰οi‰‘•lj@2016”N3ŒŽ26“ϊ(“y)E27“ϊ(“ϊ)E28“ϊ(ŒŽ)E29“ϊ(‰Ξ)@–k—’‘εŠw–ςŠw•” Œφ‰vŽΠ’c–@l “ϊ–{–ςŠw‰ο Œφ‰vŽΠ’c–@l “ϊ–{–ςŠw‰ο Œφ‰vŽΠ’c–@l “ϊ–{–ςŠw‰ο FAQ

3ŒŽ29“ϊ(火)@13:15~14:15@F‰οκ パシフィコζ¨ͺζ΅œγ€€δΌšθ­°γ‚»γƒ³γ‚ΏγƒΌγ€€3Fγ€€311+312
IS01
γƒ‰γ‚€γƒ„θ–¬ε­¦δΌšδ»£θ‘¨θ€…θ¬›ζΌ”
Special Lectures by DPhG Representatives
γ‚ͺγƒΌγ‚¬γƒŠγ‚€γ‚ΆγƒΌοΌšε€ͺη”° θŒ‚γ€ε€§ι«™ η« 

IS01-1
Raising the Gold Standard: Novel Bioisosteric Hinge-Binding Motifs for Tofacitinib-Derived JAK3 Inhibitors
Raising the Gold Standard: Novel Bioisosteric Hinge-Binding Motifs for Tofacitinib-Derived JAK3 Inhibitors
ƒVƒ“ƒ|ƒWƒXƒg F GEHRINGER M、PFAFFENROT E、FORSTER M、BAUER S. M、○LAUFER Stefan

IS01-2
The Οƒ1 receptor as target for the development of novel drugs
The Οƒ1 receptor as target for the development of novel drugs
ƒVƒ“ƒ|ƒWƒXƒg F β—‹WÜNSCH Bernhard

ŒŸυƒy[ƒW‚Ι–ί‚ι

TOP‚Φ–ί‚ι
ƒvƒ‰ƒCƒoƒV[ƒ|ƒŠƒV[‚Ι‚Β‚’‚Δ
@Copyright (C) Œφ‰vŽΠ’c–@l“ϊ–{–ςŠw‰ο